Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: The TropNet severe malaria study

42Citations
Citations of this article
70Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Intravenous artesunate improves survival in severe malaria, but clinical trial data from nonendemic countries are scarce. The TropNet severe malaria database was analyzed to compare outcomes of artesunate vs quinine treatment. Artesunate reduced parasite clearance time and duration of intensive care unit and hospital treatment in European patients with imported severe malaria.

Cite

CITATION STYLE

APA

Kurth, F., Develoux, M., Mechain, M., Clerinx, J., Antinori, S., Gjørup, I. E., … Zoller, T. (2015). Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: The TropNet severe malaria study. Clinical Infectious Diseases, 61(9), 1441–1444. https://doi.org/10.1093/cid/civ575

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free